Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D(2(long)), D3 and D4.4 receptors expressed in Chinese hamster ovary cells

British Journal of Pharmacology

Volumn 127, Issue 7, 1999, Pages 1696-1702

  Coldwell, Martyn C ^a   Boyfield, Izzy ^a   Brown, Tony ^a   Hagan, Jim J ^a   Middlemiss, Derek N ^a  

^a SmithKline Beccham Pharmaceuticals   (United Kingdom)

Author keywords

D2 receptors; D3 receptors; D4 receptors; Functional potency; Human; Ropinirole

Indexed keywords

BROMOCRIPTINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LISURIDE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SKF 104557; SKF 97930; TALIPEXOLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHO CELL; DRUG POTENCY; NONHUMAN; PRIORITY JOURNAL;

EID: 0032774493     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702673     Document Type: Article

References (40)

1. 3 subtypes. Brain Res., 649, 95-110.
2. 3 receptors GppNHp shifts are explained by the presence of more than one binding site in each clone. Br. J. Pharmacol., 108, 277P.
3. BOWEN, W.P. & JERMAN, J.C. (1995). Nonlinear regression using spreadsheets. Trends Pharm. Sci., 16, 413-417.
4. 3 receptors, expressed in the same cell line, using the Cytosensor Microphysiometer. Biochem. Soc. Trans., 24, 57S.
5. 3 dopamine receptors. Neuropsychopharmacology, 12, 335-345.
6. 1-preferring agonist. Neurosci. Lett., 196, 97-100.
7. CEDARBAUM, J.M., GANDY, S.E. & MCDOWELL, F.H. (1991). 'Early' initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias or dementia in Parkinson's Disease. Neurology, 41, 622-629.
8. 4.4 receptors separately expressed in Chinese hamster ovary cells, as measured by the Cytosensor microphysiometer. Br. J. Pharmacol., (in press).
9. 3 receptor in rat brain. Neuroscience, 65, 731-745.
10. DOMINO, E.F., LISONG, N., HUILEI, Z. & YASUKO, K. (1998). Effects of talipexole on contraversive rotation and functional impairment in MPTP-induced chronic hemiparkinsonian monkeys. Jap. J. Pharm., 77, 227-233.
11. 2 agonist. Pharmacol. Biochem. Behav., 38, 147-154.
12. GOETZ, G.G. & DIEDERICH, N.J. (1992). Dopaminergic agonists in the treatment of Parkinson's Disease. Neurologic Clinics, 10, 527-540.
13. 3 receptors. Eur. J. Pharmacol., 272, R1-R3.
14. HAGAN, J.J., MIDDLEMISS, D.N., SHARPE, P.C. & POSTE, G.H. (1997). Parkinson's Disease: prospects for improved drug therapy. Trends Pharm. Sci., 18, 156-163.
15. 3H]PD 128907. Psychopharmacology, 128, 240-247.
16. 3H]hydroxy-N,N-di-n-propyl-1-aminotetralin. Brain Res., 648, 222-228.
17. 3 receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment. Brain Res., 709, 259-264.
18. JENNER, P. & TULLOCH, I. (1997). In, Beyond the decade of the Brain, vol 2. Dopamine Agonists in early Parkinson's Disease. Ed. Olanow, C.W. & Obeso, J.A. Wells Medical Ltd.
19. KORCZYN, A.D., BROOKS, D.J., BRUNT, E.R., POEWE, W.H., RASCOL, O. & STOCCHI, F. (1998). Ropinirole versus bromocriptine in the treatment of early Parkinson's Disease: a 6 month interim report of a 3-year study. Movement Disorders, 13, 46-51.
20. LESSER, R.P., FAHN, S., SNIDER, S.R., COTE, L.J., ISGREEN, W.P. & BARRET, R.E. (1979). Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology, 29, 1253-1260.
21. 3H]hydroxy-N,N-di-n-propyl-1-aminotetralin. Proc. Natl Acad. Sci. U.S.A., 89, 8155-8159.
22. LIEBERMAN, A.N. & GOLDSTEIN, M. (1985). Bromocriptine in Parkinson's Disease. Pharmacol. Rev., 37, 217-227.
23. MARSDEN, C.D. & PARKES, J.D. (1977). Success and problems of long-term levodopa therapy in Parkinson's Disease. Lancet, i, 345-349.
24. MCCONNELL, H.M., OWICKI, J.C., PARCE, J.W., MILLER, D.L., BAXTER, G.T., WADA, H.G. & PITCHFORD, S. (1992). The Cytosensor microphysiometer: biological applications of silicon technology. Science, 257, 1096-1912.
25. MIERAU, J. (1995). Pramipexole: a dopamine-receptor agonist for treatment of Parkinson's Disease. Clini. Neuropharm., 18, S195-S206.
26. MIERAU, J., SCHNEIDER, F.J., ENSINGER, H.A., CHIO, C.L., LAJINESS, M.E. & HUFF, R.M. (1995). Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur. J. Pharmacol., 290, 29-36.
27. MIZUNO, Y., KOWA, H., NAKANISHI, T. & YANAGISAWA, N. (1993). Preliminary study of B-HT 920, a novel dopamine agonist, for the treatment of Parkinson's Disease. Drug Investigation, 5, 186-192.
28. MOLHO, E.S., FACTOR, S.A., WEINER, W.J., SANCHEZ-RAMOS, J.R., SINGER, C., SHULMAN, L., BROWN, D. & SHELDON, C. (1995). The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's Disease. J. Neural. Transm., 45, (Suppl): 225-230.
29. 2 receptors to mesostriatal regions of human forebrain. Proc. Natl. Acad. Sci. U.S.A., 91, 11271-11275.
30. OWICKI, J.C., PARCE, J.W., KERSCO, K.M., SIGAL, G.B., WADA, H.G., MIUR, V.C., BOUSSE, L.J., ROSS, K.L. & MCCONELL, H.M. (1990). Continuous monitoring of receptor mediated changes in metabolic rates in living cells. Prof. Nat. Acad. Sci. U.S.A., 87, 4007-4011.
31. RABEY, J.M. (1995). Second generation of dopamine agonists - Pros and Cons. J. Neural. Trans., 45, 213-224.
32. RINNE, U.K. (1989). Lisuride, a dopamine agonist in treatment of early Parkinson's Disease. Neurology, 39, 336-339.
33. SAGE, J.I. & MARK, M.H. (1994). Basic mechanisms of motor fluctuations. Neurology, 44 (suppl 6): S10-S14.
34. SAUTEL, F., GRIFFON, N., LEVESQUE, D., PILON, C. SCHWARTZ, J.-C. & SOKOLOFF, P. (1995). A functional test identifies dopamine agonists selective for D3 versus D2 receptors. Neuroreport, 6, 329-332.
35. SELBIE, L.A., HAYES, G. & SHINE, J. (1989). The major dopamine D2 receptor: molecular analysis of the human D2A subtype. DNA, 8, 683-689.
36. SETHI, K.D., O'BRIEN, C.F., HAMMERSTAD, J.P., ADLER, C.H. DAVIS, T.L., TAYLOR, R.L., SANCHEZ-RAMOS, J., BERTONI, J.M. & HAUSER, R.A. (1998). Ropinirole for the treatment of early Parkinson Disease. Arch. Neurol., 55, 1211-1216.
37. SOKOLOFF, P., GIROS, B., MARTRES, M.P., BOUTHENET, M.L. & SCHWARTZ, J.C. (1990). Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature, 347, 146-151.
38. SOKOLOFF, P. & SCWARTZ, J.-C. (1995). Novel DA receptors half a decade later. Trends PharmacoL Sci., 16, 270-275.
39. TILFORD, N.S., BOWEN, W.P. & BAXTER, G.S. (1995). Robofit: a versatile macro-driven template for curve fitting, analysis and presentation in Microsoft Excel. Br. J. Pharmacol., 115, 160P.
40. TULLOCH, I.F. (1997). Pharmocologic profile of ropinirole. Neurology, 49 (Suppl 1): S58-S62.